Daniel F. Tassone

Melbourne, VIC, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Editorial: Managing the Moving Target-Dose Adjustments in Inflammatory Bowel Disease.

Editorial: Managing the Moving Target-Dose Adjustments in Inflammatory Bowel Disease.

Journal: Alimentary pharmacology & therapeutics

Published: August 04, 2025

Long-Term Follow-Up of Patients in a Prospective Study of NA Discontinuation Identifies Different Patterns of HBsAg Loss.

Long-Term Follow-Up of Patients in a Prospective Study of NA Discontinuation Identifies Different Patterns of HBsAg Loss.

Journal: Alimentary pharmacology & therapeutics

Published: June 21, 2025

6-Thioguanine nucleotide levels are associated with infliximab but not adalimumab levels in inflammatory bowel disease patients on combination therapy.

6-Thioguanine nucleotide levels are associated with infliximab but not adalimumab levels in inflammatory bowel disease patients on combination therapy.

Journal: Internal medicine journal

Published: April 10, 2024

Editorial: The prevalence and outcomes of perianal Crohn's disease across treatment eras.

Editorial: The prevalence and outcomes of perianal Crohn's disease across treatment eras.

Journal: Alimentary pharmacology & therapeutics

Published: February 13, 2024

Systematic review and meta-analysis of endoscopic versus medical management of peptic ulcers with adherent clots.

Systematic review and meta-analysis of endoscopic versus medical management of peptic ulcers with adherent clots.

Journal: Journal of gastroenterology and hepatology

Published: November 07, 2023

Letter: Muscle thickness measurement using ultrasound-A step closer to the use of body composition analysis in the management of inflammatory bowel disease.

Letter: Muscle thickness measurement using ultrasound-A step closer to the use of body composition analysis in the management of inflammatory bowel disease.

Journal: Alimentary pharmacology & therapeutics

Published: September 13, 2023

Letter: Combatting sarcopenia to improve clinical outcomes in inflammatory bowel disease.

Letter: Combatting sarcopenia to improve clinical outcomes in inflammatory bowel disease.

Journal: Alimentary pharmacology & therapeutics

Published: May 18, 2023

Letter: diagnostic delay in inflammatory bowel disease.

Letter: diagnostic delay in inflammatory bowel disease.

Journal: Alimentary pharmacology & therapeutics

Published: April 24, 2023

Letter: tofacitinib in the real world - do clinical trial data stand up?

Letter: tofacitinib in the real world - do clinical trial data stand up?

Journal: Alimentary pharmacology & therapeutics

Published: January 10, 2023

Risk factors for malignancy and serious infection in patients with inflammatory bowel disease: a retrospective analysis.

Risk factors for malignancy and serious infection in patients with inflammatory bowel disease: a retrospective analysis.

Journal: Internal medicine journal

Published: December 28, 2022

Antibody response to the COVID-19 ChAdOx1nCov-19 and BNT162b vaccines after temporary suspension of DMARD therapy in immune-mediated inflammatory disease: an extension study (RESCUE 2).

Antibody response to the COVID-19 ChAdOx1nCov-19 and BNT162b vaccines after temporary suspension of DMARD therapy in immune-mediated inflammatory disease: an extension study (RESCUE 2).

Journal: RMD open

Published: November 16, 2022

Antibody response to the COVID-19 ChAdOx1nCov-19 and BNT162b vaccines after temporary suspension of DMARD therapy in immune-mediated inflammatory disease (RESCUE).

Antibody response to the COVID-19 ChAdOx1nCov-19 and BNT162b vaccines after temporary suspension of DMARD therapy in immune-mediated inflammatory disease (RESCUE).

Journal: RMD open

Published: February 22, 2022

Showing 1-12 of 16

Last Updated: 09/26/2026